IL17A and Alzheimer disease: According to recent reports, sitagliptin, a drug that modifies glucose metabolism, exhibited antioxidant and anti-apoptotic properties by altering the levels of glutamate and glutathione in the hippocampus of mice, ameliorating the accumulation of Aβ in the AD brain, and reducing the levels of inflammatory factors such as IL-17 (Figure 3) (102).